The Molecular Cytogenetics Shared Resource (MCSR) has been in development over the last three years and was formally established as a shared resource in September 2003 to provide a wide range of cytogenetic services and investigations to the OSUCCC research community. It provides state-of-the-art molecular cytogenetic technology as well as classical banded metaphase cytogenetics. Services include metaphase karyotyping of human and mouse tissue, fluorescence in situ hybridization (FISH) using many different types of probes and tissues and multicolor spectral karyotyping (SKY). Dr. Heerema, Director of the Resource, brings a wealth of experience to the MCSR with over 25 years of experience in cytogenetics and over 135 publications. Dr. Mrozek, Associate Director of the Resource, has over 20 years of experience in cytogenetics and over 80 publications. Various specimen sources, such as human and mouse cell lines and tumor samples, paraffin embedded tissues and bone marrow or blood smears are studied, dependent on the purpose of the investigation. Services accommodate different stages of sample preparation from processing fresh tissues to preparing slides from fixed cell suspensions. Probes for FISH studies include both commercially available probes and probes developed by the MCSR. Probe development offerings include growth, amplification and labeling of the probes with different fluorophores available. The types of probes include unique-sequence DNA probes, BACs, PACs and YACs. The MCSR has been widely used by the OSUCCC research community. The projects vary from karyotyping cell lines to development of FISH probes (including probes specific for canine chromosomes), identification of appropriate samples to test the probes and performing FISH on cell lines and archived specimens. From inception to date, 15 OSUCCC members have used the MCSR for 24 different projects representing all six OSUCCC programs and requiring over 2,000 hours of usage. Tools used have included SKY analysis of cell lines and patient samples, G-banded karyotyping of mouse and human tumors and various cell lines, FISH using several different probes and tissues for hybridization as well as development and labeling of some of the probes. An additional 22 projects have been identified for future service. Maintenance of high-standards, establishment and proper use of controls and control values and careful monitoring of all phases of investigation assure quality. It is expected that future use of the MCSR will continue to be extensive, as investigators have indicated continuing need for the services offered.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA016058-32
Application #
7630216
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2006-12-01
Budget End
2007-11-30
Support Year
32
Fiscal Year
2007
Total Cost
$111,460
Indirect Cost
Name
Ohio State University
Department
Type
DUNS #
832127323
City
Columbus
State
OH
Country
United States
Zip Code
43210
Baldassari, Federica; Zerbinati, Carlotta; Galasso, Marco et al. (2018) Screen for MicroRNA and Drug Interactions in Breast Cancer Cell Lines Points to miR-126 as a Modulator of CDK4/6 and PIK3CA Inhibitors. Front Genet 9:174
Yang, Xiaosong; Pan, You; Qiu, Zhaojun et al. (2018) RNF126 as a Biomarker of a Poor Prognosis in Invasive Breast Cancer and CHEK1 Inhibitor Efficacy in Breast Cancer Cells. Clin Cancer Res 24:1629-1643
Ozawa, Patricia Midori Murobushi; Alkhilaiwi, Faris; Cavalli, Iglenir João et al. (2018) Extracellular vesicles from triple-negative breast cancer cells promote proliferation and drug resistance in non-tumorigenic breast cells. Breast Cancer Res Treat 172:713-723
Ngankeu, Apollinaire; Ranganathan, Parvathi; Havelange, Violaine et al. (2018) Discovery and functional implications of a miR-29b-1/miR-29a cluster polymorphism in acute myeloid leukemia. Oncotarget 9:4354-4365
Lopez, Cecilia M; Yu, Peter Y; Zhang, Xiaoli et al. (2018) MiR-34a regulates the invasive capacity of canine osteosarcoma cell lines. PLoS One 13:e0190086
Victor, Aaron R; Weigel, Christoph; Scoville, Steven D et al. (2018) Epigenetic and Posttranscriptional Regulation of CD16 Expression during Human NK Cell Development. J Immunol 200:565-572
Lampis, Andrea; Carotenuto, Pietro; Vlachogiannis, Georgios et al. (2018) MIR21 Drives Resistance to Heat Shock Protein 90 Inhibition in Cholangiocarcinoma. Gastroenterology 154:1066-1079.e5
Le Gallo, Matthieu; Rudd, Meghan L; Urick, Mary Ellen et al. (2018) The FOXA2 transcription factor is frequently somatically mutated in uterine carcinosarcomas and carcinomas. Cancer 124:65-73
Jones, Jeffrey A; Mato, Anthony R; Wierda, William G et al. (2018) Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre, open-label, phase 2 trial. Lancet Oncol 19:65-75
Madan, Esha; Parker, Taylor M; Bauer, Matthias R et al. (2018) The curcumin analog HO-3867 selectively kills cancer cells by converting mutant p53 protein to transcriptionally active wildtype p53. J Biol Chem 293:4262-4276

Showing the most recent 10 out of 2602 publications